ClinicalTrials.gg
Status unknownNCT05775575Updated Mar 20, 2023

A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer

A Phase 1/2 interventional study of TQB3909 tablets in Advanced Breast Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-03-20.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
65
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited — 11 open to participants now, 16 under way, 8 of them phase 3. Breast Neoplasms · Sino Biopharmaceutical Limited.

Planned enrollment
19th of 28
65 · median 138
Started
2023
with 4 others
Phase 1/2
5 of 28
2 open now
Registered
9th of 28
by date

Among the 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited, this one is the 19th largest by planned enrollment, is one of 5 that started in 2023, is one of 5 in phase 1/2, and was the 9th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

TQB3909 is an inhibitor targeting B-cell lymphoma (BCL)-2 protein. By binding to BCL-2 protein, TQB3909 releases Pro apoptotic proteins such as BCL-2-Anatagonist/Killer 1(BAK), BCL-2 associated X (BAX) protein and BCL-2 associated death (BAD) protein, promotes the release of cytochrome c from mitochondria, phosphatidylserine eversion, stimulates caspase 3/7 activity and caspase 3/9 cleavage, and induces apoptosis.

03

Conditions studied

  • Advanced Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Evidence of a personally signed and dated document indicating that the patient has been informed of all pertinent aspects of the study.
  • Age: 18 to 75 years old; female patient, an (ECOG) performance status of 0 to 1.
  • Histopathologically confirmed HR positive and negative advanced or breast cancer.
  • Patients who have been treated with endocrine therapy and have experienced disease progression.
  • Patients previously treated with any CDK4/6 inhibitor and not treated with BCL-2 inhibitor.
  • Has at least one according to (RECIST) v1.1 criteria
  • The main organs function well;
  • Female patient had no plans to become pregnant and voluntarily took effective measures from agree with the study to at least 6 months after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

    1. Concomitant disease and medical history:

      1. There were other malignant tumors in 3 years before the first medication.
      2. Has multiple factors affecting oral medication;
      3. Unalleviated toxicity ≥ grade 1 due to any previous therapy;
      4. Major surgical treatment, open and obvious traumatic injury were performed within 28 days before the study; e.Arteriovenous thrombotic events occurred within 6 months before the first medication, such as cerebrovascular accident (including , cerebral hemorrhage, cerebral infarction), deep venous thrombosis and pulmonary embolism; f.Have a history of psychotropic drug abuse and can not quit or have mental disorders; g.Subjects with any severe and / or uncontrolled disease included: Cirrhosis, active hepatitis, history of immunodeficiency;
  • Tumor-related symptoms and treatment:

    1. Has central nervous system (CNS) and/or cancerous meningitis or ;
    2. have received radiotherapy, other antineoplastic therapy within 2 weeks prior to the first dose;
    3. Has uncontrollable pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.
  • Known to TQB3909, LHRH agonists (e.g., goserelin), or any .
  • Subjects who have received the vaccine within 28 days prior to the first dose, or are planning to receive the vaccine during the study period.
  • Has Participated in other clinical trials within 4 weeks before first dose.
  • According to the judgement of the investigators, there are other factors that may lead to the termination of the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
65 participants (estimated)

Study arms

  • Experimental
    TQB3909 tablets

    200-1000mg of TQB3909 tablets once a day; Oral administration under fast condition, 28 days as a cycle.

    Drug: TQB3909 tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicity (DLT)

    DLT will be defined as toxicities that meet pre-defined severity criteria(according to the NCI CTCAE v5.0 toxicity assessment criteria), and assessed as having a suspected relationship to study drug that occurred from the first dose to the end of the first treatment cycle.

    Time frame: At the end of Cycle 1 (Cycle 1, Day 28)

  2. Maximum tolerated dose (MTD)

    MTD was defined as the highest dose at which dose-limiting toxicity (DLT) occurred in less than 33% of patients.

    Time frame: At the end of Cycle 1 (Cycle 1, Day 28)

  3. Recommended Phase II Dose (RP2D)

    DLT describes side effects of a drug or other treatment that are serious enough to evaluate RP2D of TQB3909 tablets in adult patients with Breast cancers

    Time frame: Baseline up to 24 months

Secondary outcomes

  1. Time to reach maximum (peak)plasma concentration (Tmax)

    To characterize the pharmacokinetics of TQB3909 by assessment of time to reach maximum plasma concentration after single and multiple dosing.

    Time frame: before administration at Day 1, Cycle1 Day7,Cycle1 Day14, Cycle1 Day28; 1, 2, 4, 6, 8, 10,24,48, and 72 hours after-dose at Day 1; 1, 2, 4, 6, 8, 10, and 24 hours after-dose at Cycle 1 Day 28.

  2. Peak concentration (Cmax)

    Maximum observed concentration (Cmax) of TQB3909

    Time frame: before administration at Day 1, Cycle1 Day7,Cycle1 Day14, Cycle1 Day28; 1, 2, 4, 6, 8, 10,24,48, and 72 hours after-dose at Day 1; 1, 2, 4, 6, 8, 10, and 24 hours after-dose at Cycle 1 Day 28.

  3. Terminal half-life (T1/2)

    Pharmacokinetics parameters to evaluate the half life of TQB3909 (T1/2)

    Time frame: before administration at Day 1, Cycle1 Day7,Cycle1 Day14, Cycle1 Day28; 1, 2, 4, 6, 8, 10,24,48, and 72 hours after-dose at Day 1; 1, 2, 4, 6, 8, 10, and 24 hours after-dose at Cycle 1 Day 28.

  4. Area under the plasma concentration-time curve from time zero to time t (AUC0-t)

    To characterize the pharmacokinetics of TQB3909 by assessment of area under the plasma concentration time curve from the first dose to a certain time point.

    Time frame: before administration at Day 1, Cycle1 Day7,Cycle1 Day14, Cycle1 Day28; 1, 2, 4, 6, 8, 10,24,48, and 72 hours after-dose at Day 1; 1, 2, 4, 6, 8, 10, and 24 hours after-dose at Cycle 1 Day 28.

  5. Maximum (peak) steady-state plasma drug concentration during a dosage interval (Cmax,ss)

    Cmax,ss is the steady state maximum concentration of TQB3909.

    Time frame: before administration at Day 1, Cycle1 Day7,Cycle1 Day14, Cycle1 Day28; 1, 2, 4, 6, 8, 10,24,48, and 72 hours after-dose at Day 1; 1, 2, 4, 6, 8, 10, and 24 hours after-dose at Cycle 1 Day 28.

  6. Minimum steady-state plasma drug concentration during a dosage interval (Cmin,ss)

    Cmin,ss is the minimum plasma concentration of TQB3909.

    Time frame: before administration at Day 1, Cycle1 Day7,Cycle1 Day14, Cycle1 Day28; 1, 2, 4, 6, 8, 10,24,48, and 72 hours after-dose at Day 1; 1, 2, 4, 6, 8, 10, and 24 hours after-dose at Cycle 1 Day 28.

  7. Clinilca Benefit Rate (CBR)

    Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).

    Time frame: From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100 weeks.

  8. Objective Response Rate (ORR)

    Defined as the percentage of Complete Response (CR) plus partial response (PR) assessed by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 criteria

    Time frame: From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100 weeks.

07

Study locations

1 of 1 sites recruiting
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2023, 9 months after the start.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 9 months is below that.

Counting every sponsor, half of 328 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2022
First posted
Mar 20, 2023
StartActual
Mar 2, 2023
Primary completionEst.
Dec 2023
CompletionEst.
Dec 2023
Last update
Mar 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05775575
Responsible party
Sponsor
First posted
Mar 20, 2023
Start date
Mar 2, 2023
Primary completion
Dec 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
Mar 20, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bcl-2 Inhibitor TQB3909

Start the discussion